Skip to content

Discontinued — last reported Q1 '25

Income Tax at other companies

Pfizer logo
PfizerPFE
$461M+344%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$104M+8.0%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$35.68M-31.9%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$347K-99.5%
Insmed logo
InsmedINSM
$1.47M+60.6%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$0

Segments

By segment

See full
All Other Segments$12.22M-80.9%

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s income tax?
Sarepta Therapeutics, Inc. (SRPT) reported income tax of $63.99M in Q1 2025.
How has Sarepta Therapeutics, Inc.'s income tax changed year-over-year?
Sarepta Therapeutics, Inc.'s income tax increased by 1100.8% year-over-year, from $5.33M to $63.99M.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.